

## **Technology**



### **Tempered expectations**

#### We expect cautious FY26E guidance amid an uncertain backdrop

- Mar'25), the discretionary spending recovery that we saw picking up in 1HFY25 has been stuck in the second gear; and clients are likely to be in wait-and-watch mode as they take stock of the trade war, a slower Fed rate cut cycle, and other macro-economic risks. The net result of this will be a stop-start recovery in discretionary spending, pegging FY26E revenue growth for most large-caps in the range of 2-5% in constant currency (CC). There are three key questions that we would like to address: 1) Is there an upside risk to FY26 growth estimates? 2) Is feeble large-cap growth already in the price? and 3) Is further de-rating possible if the trade war escalates and US/Europe macro worsens?
- Is there upside risk to growth estimates? As shown in Exhibit 6, deal TCV for FY25E for most large-caps could be down 15-25% vs FY24 (Infosys at -32% and TechM at +34% stand out). This most likely entails an inferior 1HFY26 vs. 1HFY25, and unless deal activity meaningfully accelerates in 1HCY25, the upside risk to FY26 estimates is limited.
- Is the lower growth already priced in? We believe the growth deceleration is largely priced in, but we note that the NSE IT Index currently trades at a 28% premium to the Nifty (5/10-year avg of 29%/14%), and any re-rating is contingent on earnings beat.
- **Is further de-rating possible?** We believe most large-caps are trading at 5-year average PE multiples, and further de-rating is unlikely.
- All eyes now will be on FY26 guidance; we expect Infosys to guide for 2.5%-5% CC growth for FY26; and expect HCLT's top end to be in a similar range.
- For 4Q, we expect aggregate revenue for our coverage universe to grow by 7.8% YoY, while EBIT and PAT are likely to grow at 7.1% and 5.7% YoY (all in INR terms)
- **Cross-currency impact for 4Q**: On an average, we expect ~50-80bp cross-currency headwinds for our coverage on a sequential basis.
- We expect revenue growth of Tier-I companies to be in the range of -1.0% to flat QoQ CC. Revenue of Tier-II players is expected to grow to the tune of -0.5% to ~5% QoQ in CC terms.

#### **Growth expectations across our coverage**

- We expect INFO and TCS to report a revenue decline of 1.0% and 0.5% QoQ cc, respectively, whereas HCLT is anticipated to clock a 0.6% decline in 4QFY25, driven by tapering of deal ramp-ups in telecom and seasonal weakness in the P&P segment. Meanwhile, TECHM is likely to post a 0.8% QoQ revenue decline and Wipro may report flat revenue QoQ. LTIM could deliver 0.2% QoQ cc growth despite productivity pass-back in a key account spilling into 4Q.
- Among mid-tier firms, we expect LTTS to lead the pack with ~15% cc QoQ revenue growth (organic growth of 7%), driven by broad-based growth and inorganic contribution from Intelliswift. Persistent/Coforge are also likely to deliver 4.0%/3.0% cc QoQ growth, while Mphasis could post 3.0% cc QoQ growth.

■ We expect Cyient DET to report yet another weak quarter, with flat QoQ revenue. The company may fall short of its revised FY25 guidance of ~2.7% YoY cc decline due to challenges in its key vertical. We are factoring in a modest cross-currency headwind for most companies (~50-80bp impact).

#### Margins to remain range-bound this quarter

- We expect TCS EBIT margins to remain flat QoQ despite BSNL ramp-down owing to headwinds from talent investments. HCLT's margins may decline ~190bp, led by wage hikes (50-60bp), slower growth, and decline in the high-margin P&P segment. Infosys may see a 70bp dip due to wage hikes and visa costs, partially offset by cost optimizations and lower third-party spend.
- LTIM margins are likely to stay flat at 13.8%. Wipro margins should remain around 17.0-17.5%, with no major headwinds.
- The net headcount addition would be lower across the board, owing to a muted demand recovery.
- Among mid-caps, Coforge margins may rise to 12.9%, supported by lower merger costs and operational gains. Cyient DET margins are likely to be ~13.5%, revised down from 16% due to delayed revenue realization. LTTS may see a 90bp QoQ margin dip, driven by Intelliswift consolidation (150bp impact) and SG&A investments.

#### **TECHM and COFORGE remain our top picks**

- We prioritize correct positioning over predictability, favoring bottom-up transformation and margin-driven stories over top-down discretionary names.
- Among Tier-I players, we prefer **TECHM**, driven by early signs of transformation under new leadership and improving execution in BFSI. Margin expectations are now more reasonable, and niche offerings are resonating well. We believe TechM's transformation remains relatively decoupled from discretionary spends. With further scope for telecom recovery and operational efficiency, we see room for sustained margin improvement going forward. We continue to like HCLT for its all-weather portfolio, and believe TCS offered a fair risk-reward balance.
- Among Tier-II players, our top pick is COFORGE. Its strong offerings in BFS and insurance should enable it to participate in a demand recovery, and a strong TCV also indicates a robust near-term growth outlook. We believe COFORGE's organic business is in great shape and early cross-selling initiatives between COFORGE and Cigniti indicate that COFORGE could engineer a growth turnaround at Cigniti earlier than expected.

Exhibit 1: Expect Tier-I companies' revenue (USD) to decline by 1.0%


		R	evenue (USD	m)		Revenue (INR b)						
Company	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)		
TCS	7,477	7,539	-0.8%	7,363	1.5%	648	640	1.3%	612	5.9%		
INFO	4,869	4,939	-1.4%	4,564	6.7%	422	418	1.1%	379	11.3%		
HCLT	3,502	3,533	-0.9%	3,430	2.1%	304	299	1.6%	285	6.5%		
WPRO	2,608	2,629	-0.8%	2,657	-1.8%	227	223	1.7%	222	2.2%		
TECHM	1,544	1,567	-1.5%	1,548	-0.3%	134	133	0.8%	129	4.0%		
LTIM	1,136	1,139	-0.2%	1,069	6.2%	99	97	2.0%	89	10.8%		
Tier I aggregate	21,136	21,346	-1.0%	20,632	2.4%	1,833	1,809	1.4%	1,716	6.8%		
		E	BIT margin (9	<b>%)</b>		Adjusted PAT (INR b)						
Company	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)		
TCS	24.5	24.5	-	26.0	-150.0	125.6	124.4	0.9%	125.0	0.4%		
INFO	20.6	21.3	-70.0	20.1	50.0	66.7	68.2	-2.2%	60.8	9.7%		
HCLT	17.6	19.5	-190.0	17.6	-	42.8	45.9	-6.9%	40.0	7.0%		
WPRO	17.5	17.5	10.0	15.9	160.0	32.9	33.7	-2.1%	28.6	15.3%		
TECHM	10.3	10.2	10.0	7.4	290.0	10.0	9.8	1.3%	9.7	3.0%		
LTIM	13.8	13.8	-	14.7	-90.0	11.5	10.9	6.1%	11.0	4.7%		
Tier I aggregate	20.0	20.4	-50.0	20.0	-	289	293	-1.2%	275	5.2%		

Exhibit 2: Expect Tier-II companies' revenue (USD) to be up 4.2% QoQ

		•	•	<u> </u>								
		Re	venue (USD r	n)		Revenue (INR b)						
Company	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)		
LTTS	357	312	14.6%	305	17.2%	31.0	26.5	16.8%	25.4	22.1%		
MPHL	430	419	2.7%	411	4.7%	37.3	35.6	4.9%	34.2	9.2%		
COFORGE	406	397	2.2%	287	41.5%	35.2	33.2	6.0%	23.6	49.2%		
PSYS	374	360	3.8%	311	20.3%	32.4	30.6	5.9%	25.9	25.2%		
ZENT	156	157	-0.5%	148	5.5%	13.6	13.3	2.2%	12.3	10.2%		
CYL	174	175	-1.0%	179	-3.2%	15.0	14.8	1.6%	14.9	1.0%		
Tier II aggregate	1,897	1,820	4.2%	1,641	15.6%	164.5	154.0	6.8%	136.2	20.8%		
		E	BIT margin (%	5)		Adjusted PAT (INR b)						
Company	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)	4QFY25	3QFY25	QoQ (%)	4QFY24	YoY (%)		
LTTS	15.0	15.9	-90.0	16.9	-190.0	3.8	3.2	20.9%	3.4	12.3%		
MPHL	15.4	15.3	10.0	14.9	50.0	4.5	4.3	5.7%	3.9	15.1%		
COFORGE	12.9	11.8	110.0	14.5	-160.0	3.0	2.2	39.7%	2.3	31.2%		
PSYS	14.8	14.9	-10.0	14.5	40.0	3.9	3.7	4.7%	3.2	23.9%		
ZENT	14.0	13.8	20.0	14.6	-60.0	1.7	1.6	4.0%	1.7	-4.2%		
CYL	13.5	13.5	-	16.0	-250.0	1.8	1.3	36.9%	1.9	-7.3%		
Tier II aggregate	14.4	14.3	10.0	15.2	-80.0	18.7	16.2	15.3%	16.4	13.8%		


Source: Company, MOFSL

Exhibit 3: Tier II companies may outperform Tier I companies



Source: MOFSL, Company

Exhibit 4: Margins largely remain range-bound for most Tier-I and Tier-II companies




Source: MOFSL, Company

Exhibit 5: Cross-currency impact on 4Q USD growth

	CC USD growth QoQ (%)	USD growth QoQ (%)	Cross-currency impact (bp)
TCS	-0.5%	-0.8%	-30
INFO	-1.0%	-1.4%	-40
HCLT	-0.6%	-0.9%	-30
WPRO	0.0%	-0.8%	-80
TECHM	-0.8%	-1.5%	-70
LTIM	0.2%	-0.2%	-40
LTTS	15.0%	14.6%	-40
MPHL	3.0%	2.7%	-30
COFORGE	3.0%	2.2%	-80
PSYS	4.0%	3.8%	-20
ZENT	-0.5%	-0.5%	-
CYL (DET)	0.0%	-1.0%	-100


Source: Company, MOFSL

Exhibit 6: We expect deal TCV growth to remain subdued, except for a few companies, as the demand environment appears indecisive



Source: Company, MOFSL

Exhibit 7: Nifty IT P/E reverts to 5-year avg. premium of 29%; re-rating from here hinges on an earnings beat




Source: Company, MOFSL

4

March 2025

Exhibit 8: Large-caps trade ~5% below, while mid-caps trade ~12% above their 5-yr avg P/E; further large-cap de-rating appears unlikely



Source: Company, MOFSL

**Exhibit 9: Summary of quarterly performance estimates** 

	CMP		S	Sales (INR b	p)		EBIT (INR b	)	Adjuste	d net profi	t (INR b)
Companies	(INR)	Rating	Mar'25E	Variance YoY (%)	Variance QoQ (%)	Mar'25E	Variance YoY (%)	Variance QoQ (%)	Mar'25E	Variance YoY (%)	Variance QoQ (%)
TCS	3,606	Buy	648.3	5.9%	1.3%	158.8	-0.2%	1.4%	125.6	0.4%	0.9%
INFO	1,571	Neutral	422.1	11.3%	1.1%	87.0	14.1%	-2.4%	66.7	9.7%	-2.2%
HCLT	1,593	Buy	303.6	6.5%	1.6%	53.4	6.4%	-8.3%	42.8	7.0%	-6.9%
WPRO	262	Sell	227.1	2.2%	1.7%	39.8	12.5%	2.1%	32.9	15.3%	-2.1%
TECHM	1,418	Buy	133.9	4.0%	0.8%	13.8	45.7%	2.1%	10.0	3.0%	1.3%
LTIM	4,491	Buy	98.5	10.8%	2.0%	13.6	3.9%	2.3%	11.5	4.7%	6.1%
MPHL	2,500	Neutral	37.3	9.2%	4.9%	4.6	8.6%	10.2%	3.8	12.3%	20.9%
LTTS	4,502	Neutral	31.0	22.1%	16.8%	5.8	13.2%	5.4%	4.5	15.1%	5.7%
PSYS	5,514	Buy	32.4	25.2%	5.9%	4.5	33.0%	15.7%	3.0	31.2%	39.7%
COFORGE	8,109	Buy	35.2	49.2%	6.0%	4.8	28.3%	5.5%	3.9	23.9%	4.7%
CYL	1,265	Sell	15.0	1.0%	1.6%	1.9	5.8%	3.6%	1.7	-4.2%	4.0%
ZENT	701	Neutral	13.6	10.2%	2.2%	2.0	-14.9%	1.8%	1.8	-7.3%	36.9%
Sector aggregate (INR b)			1,998	7.8%	1.8%	390	7.1%	-0.4%	308	5.7%	-0.3%

Source: Company, MOFSL

**Exhibit 10: Comparative valuations** 

Company	CMP	•	Target	Upside/		EPS (INR)		EPS CAGR (%)		P/E (x)	
	(INR)	(IINK D)	Price	Downside	FY25E	FY26E	FY27E	FY24-27E	FY25E	FY26E	FY27E
TCS	3,606	13,047	4,050	12%	134.9	148.5	159.9	8.2	26.7	24.3	22.5
INFO	1,571	6,523	1,650	5%	63.5	68.6	74.0	8.2	24.7	22.9	21.2
HCLT	1,593	4,322	1,800	13%	63.7	69.0	75.8	9.4	25.0	23.1	21.0
WPRO	262	2,746	240	-8%	12.2	12.7	13.1	8.8	21.6	20.7	20.0
TECHM	1,418	1,389	1,950	37%	46.1	61.2	75.3	22.6	30.8	23.2	18.8
LTIM	4,491	1,331	6,250	39%	156.1	175.5	204.2	9.7	28.8	25.6	22.0
MPHL	2,500	475	2,550	2%	89.5	100.0	109.6	10.3	27.9	25.0	22.8
LTTS	4,502	477	4,700	4%	126.4	150.8	172.2	11.9	35.6	29.9	26.1
PSYS	5,514	859	6,250	13%	90.9	113.7	138.1	22.5	60.7	48.5	39.9
COFORGE	8,109	542	11,000	36%	127.9	233.8	282.1	29.9	63.4	34.7	28.7
CYL	1,265	140	1,200	-5%	54.4	74.2	83.0	10.1	23.2	17.0	15.2
ZENT	701	159	770	10%	28.0	32.0	36.1	7.5	25.1	21.9	19.4

Source: Company, MOFSL

The tables below provide a snapshot of actual and estimated numbers for IT companies under the MOFSL coverage universe. Highlighted columns indicate the quarter/financial year under review.

### Coforge

#### Buy

#### CMP INR8,109 | TP: INR11,000 (+36%)

#### EPS CHANGE (%): FY25 | 26 | 27: -0.2 | -0.3 | -4.3

- Revenue growth is expected to be ~3.0% QoQ CC, supported by robust organic growth and reversal of furloughs impact.
- We expect 80bp expansion in reported EBITDA margin.
   EBIT margin should rise to 12.9% due to lower merger expenses, though ESOP costs in 4Q will weigh on margins.
- Deal momentum is expected to stay robust, supported by a healthy pipeline in both BFS and Insurance verticals.
- Key things to watch out for: further benefits from Cigniti's cross-selling and deal TCV in BFS and Insurance (~48.5% of revenue).

**Quarterly Performance (IND-AS)** 

Y/E March		FY2	24			FY2	5E		FY24	FY25E
(Consolidated)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Rev. (USD m)	272	278	282	287	291	369	397	406	1,119	1,464
QoQ (%)	2.8	2.3	1.4	1.7	1.6	26.8	7.5	2.2	11.7	30.8
Revenue (INR m)	22,210	22,762	23,233	23,585	24,008	30,623	33,182	35,184	91,790	1,22,997
YoY (%)	21.4	16.2	13.0	8.7	8.1	34.5	42.8	49.2	14.5	34.0
GPM (%)	30.7	32.5	33.1	34.1	33.0	32.4	33.2	33.6	32.6	33.1
SGA (%)	14.7	14.9	15.1	15.1	15.1	15.9	15.4	15.3	15.0	15.4
EBITDA (INRm)	3,329	3,473	4,012	4,259	4,099	4,840	5,190	5,805	15,074	19,934
EBITDA Margin (%)	15.0	15.3	17.3	18.1	17.1	15.8	15.6	16.5	16.4	16.2
EBIT (INRm)	2,572	2,701	3,201	3,413	3,284	3,597	3,922	4,539	11,888	15,341
EBIT Margin (%)	11.6	11.9	13.8	14.5	13.7	11.7	11.8	12.9	13.0	12.5
Other income	-152	-295	-257	-452	-272	-173	-327	-35	-1,156	-807
ETR (%)	21.5	21.9	17.5	18.0	31.8	25.5	25.5	24.5	19.5	26.1
Minority Interest	-104.0	-69.0	-48.0	-55.0	-61.0	-314.0	-404.0	-390.2	-276.0	-1,169.2
Reported PAT	1,666	1,809	2,380	2,294	1,344	2,021	2,155	3,010	8,150	8,530
QoQ (%)	-28.4	8.6	31.6	-3.6	-41.4	50.4	6.6	39.7		
YoY (%)	11.0	-10.3	4.3	-1.4	-19.4	11.7	-9.4	31.2	0.3	4.7
Extra-ordinary items	165	0	0	96	953	290	162	0	261	1,405
Adj. PAT	1,831	1,809	2,380	2,390	2,297	2,311	2,317	3,010	8,411	9,935
EPS (INR)	29.2	29.0	38.1	36.2	20.8	30.1	31.9	44.6	128.6	127.9

### **Cyient**

#### Sel

#### CMP INR1,265 | TP: INR1,200 (-5%)

#### Expect flat QoQ CC growth for DET in 4QFY25, with FY25 revenue now seen declining ~2.7% YoY (vs. earlier flat guidance) due to ramp-up delays.

 Sustainability remains weak on project delays, while the Connectivity vertical has seen robust execution and rampups in North American deals.

#### EPS CHANGE (%): FY25 | 26 | 27: 0.2 | 0.4 | -2.2

- 4QFY25-exit EBIT margin is expected to be around 13.5% for DET business (vs. earlier forecast of 16%), due to delayed revenue realization within the year.
- We expect initial FY26 DET revenue growth guidance to be muted.

**DET Quarterly Performance** 

Y/E March		FY2	4			FY2	5		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	177	178	179	179	170	173	175	174	714	691
QoQ (%)	0.5	0.7	0.4	0.1	-5.4	2.0	1.3	-1.0	12.9	-3.2
Revenue (INR m)	14,546	14,762	14,914	14,892	14,144	14,496	14,799	15,043	59,114	58,482
YoY (%)	37.2	22.5	8.1	2.8	-2.8	-1.8	-0.8	1.0	16.1	-1.1
GPM (%)	39.8	40.2	40.0	39.8	39.5	39.7	38.9	38.9	39.9	39.2
SGA (%)	19.5	19.7	20.0	19.7	21.9	21.5	21.6	21.5	19.7	21.6
EBITDA	2,956	3,036	2,981	2,987	2,487	2,642	2,562	2,617	11,960	10,308
EBITDA Margin (%)	20.3	20.6	20.0	20.1	17.6	18.2	17.3	17.4	20.2	17.6
EBIT	2,336	2,439	2,385	2,385	1,903	2,058	1,995	2,031	9,545	7,987
EBIT Margin (%)	16.1	16.5	16.0	16.0	13.5	14.2	13.5	13.5	16.1	13.7
Other income	-122	-180	-139	-107	-54	282	-338	75	-548	-35
ETR (%)	23.1	23.5	23.1	23.8	23.5	24.5	25.3	25.0	23.4	24.6
Adj. PAT	1,703	1,728	1,727	1,735	1,414	1,766	1,238	1,579	6,893	5,997
QoQ (%)	6.1	1.5	-0.1	0.5	-18.5	24.9	-29.9	27.5		
YoY (%)	56.4	60.4	17.3	8.1	-17.0	2.2	-28.3	-9.0	31.5	-13.0
EPS (INR)	15	16	16	16	13	16	11	14	63	55

### **HCL Technologies**

### Buy

(INR Bn)

#### CMP INR1,593 | TP: INR1,800 (+13%)

#### EPS CHANGE (%): FY25 | 26 | 27: 0.1 | 0.0 | 0.2

- HCL is expected to report 0.6% QoQ CC decline due to planned megadeal reductions, tapering of deals in telecom, and seasonal weakness in the P&P segment (-12% QoQ).
- ER&D and manufacturing softness may weigh on 4Q performance, while BFSI stays stable, and Hi-tech shows early signs of revival.
- Margins are expected to decline by 190bp QoQ in 4Q, driven by a 50-60bp impact from wage hikes and highmargin P&P business de-growth.
- We expect the company to provide initial FY26 revenue growth guidance of ~3-5%, with stable EBIT margin.

  Commentary on deal TCV and the demand trends around BFSI, Hi-tech & ERD space would be watched out for.

#### **Quarterly Performance**

Y/E March		FY2	4			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	3,200	3,225	3,415	3,430	3,364	3,445	3,533	3,502	13,270	13,844
QoQ (%)	-1.1	0.8	5.9	0.4	-1.9	2.4	2.5	-0.9	5.4	4.3
Revenue (INR b)	263	267	284	285	281	289	299	304	1,099	1,172
YoY (%)	12.1	8.0	6.5	7.1	6.7	8.2	5.1	6.5	8.3	6.6
GPM (%)	35.6	36.2	36.7	35.0	34.5	34.9	35.6	34.0	35.9	34.8
SGA (%)	13.6	12.4	11.5	12.0	12.4	11.5	11.3	11.5	12.4	11.7
EBITDA	55	59	67	61	58	64	69	64	242	254
EBITDA Margin (%)	20.8	22.3	23.5	21.4	20.6	22.1	23.0	21.1	22.0	21.7
EBIT	45	49	56	50	48	54	58	53	200	213
EBIT Margin (%)	17.0	18.5	19.7	17.6	17.1	18.6	19.5	17.6	18.2	18.2
Other income	2	2	3	3	9	3	3	4	9	19
ETR (%)	24.8	25.3	25.9	24.2	25.4	25.5	25.1	25.0	25.1	25.2
Adjusted PAT	35	38	44	40	43	42	46	43	157	174
QoQ (%)	-11.2	8.4	13.5	-8.4	6.8	-0.5	8.4	-6.9		
YoY (%)	7.6	9.8	6.2	0.1	20.5	10.5	5.5	7.2	5.7	10.5
EPS	13.0	14.1	16.0	14.7	15.7	15.6	16.9	15.8	57.9	63.7

### Infosys Neutral

#### CMP INR1,571 | TP: INR1,650 (+5%)

**Quarterly Performance (IFRS)** 

YoY (%)

EPS (INR)

- EPS CHANGE (%): FY25 | 26 | 27: 0.2 | -0.5 | -1.0
- INFO is likely to clock 1.0% QoQ CC decline for 4Q at the top end of guidance.
- Operating margin is expected to dip by 70bp due to wage hike and visa cost impact, though cost optimizations and lower third-party expenses may partially offset the impact.
- While the deal pipeline is healthy, closures are facing delays due to slower decision-making. Clients remain focused on cost take-outs over discretionary spending, with tariff wars adding pressure.
- We expect the company to provide initial FY26 revenue growth guidance band of 2.5-5%.

Y/E March	FY24 FY25E								FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	<b>3Q</b>	4QE		
Revenue (USD m)	4,617	4,718	4,663	4,564	4,714	4,894	4,939	4,869	18,562	19,416
QoQ (%)	1.4	2.2	-1.2	-2.1	3.3	3.8	0.9	-1.4	1.9	4.6
Revenue (INR b)	379	390	388	379	393	410	418	422	1,537	1,643
YoY (%)	10.0	6.7	1.3	1.3	3.6	5.1	7.6	11.3	4.7	6.9
GPM (%)	30.5	30.7	29.8	29.5	30.9	30.5	30.3	29.5	30.1	30.3
SGA (%)	9.6	9.5	9.3	9.4	9.8	9.4	8.9	8.9	9.4	9.3
EBITDA	90	95	91	88	93	98	100	98	364	390
EBITDA Margin (%)	23.8	24.3	23.6	23.1	23.8	23.8	24.0	23.3	23.7	23.7
EBIT	79	83	80	76	83	86	89	87	317	345
EBIT Margin (%)	20.8	21.2	20.5	20.1	21.1	21.1	21.3	20.6	20.7	21.0
Other income	5	5	7	7	7	6	8	6	23	27
ETR (%)	28.9	29.1	29.1	26.8	29.3	29.6	29.5	28.5	28.5	29.2
PAT	59	62	61	61	64	65	68	67	243	264
QoQ (%)	-3.0	4.5	-1.7	-0.5	4.8	2.2	4.6	-2.0		

March 2025 7

-7.3

14.7

3.2

15.0

10.9

-0.9

14.7

7.1

15.4

4.7

15.7

11.5

9.8

16.1

1.0

58.4

8.3

63.5

## LTIMindtree Buy

#### CMP INR4,491 | TP: INR6,250 (+39%)

- LTIM is expected to report flat CC growth in 4Q, impacted by slower discretionary spending and deal ramp-down. Further, Hi-tech is expected to decline, impacted by a productivity pass-back in a key account spilling into 4Q.
- Margins are expected to remain flat at 13.8%, supported by gradual improvement in utilization.

- EPS CHANGE (%): FY25 | 26 | 27: -1.6 | -1.4 | -1.4
- BFSI is holding up well with some softness in insurance; manufacturing is stable; CPG and retail remain steady, while travel is seeing some pressure.
- We expect the initial commentary on FY26 growth to remain muted, though margin guidance should be maintained or even increased, as most major margin headwinds appear to be behind.

#### **Quarterly Performance**

Y/E March		FY2	4			FY25		FY24	FY25E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	1,059	1,076	1,084	1,069	1,096	1,127	1,139	1,136	4,287	4,498
QoQ (%)	0.1	1.6	0.8	-1.3	2.5	2.8	1.1	-0.2	4.4	4.9
Revenue (INR b)	87	89	90	89	91	94	97	99	355	381
YoY (%)	13.8	8.2	4.6	2.3	5.1	5.9	7.1	10.8	7.0	7.2
GPM (%)	31.6	31.4	29.9	29.8	30.3	30.8	28.8	29.0	30.7	29.7
SGA (%)	12.8	13.1	12.3	12.5	12.7	12.8	12.3	12.5	12.7	12.6
EBITDA	16	16	16	15	16	17	16	16	64	65
EBITDA Margin (%)	18.8	18.3	17.6	17.3	17.6	18.0	16.5	16.5	18.0	17.1
EBIT	15	14	14	13	14	15	13	14	56	55
EBIT Margin (%)	16.7	16.0	15.4	14.7	15.0	15.5	13.8	13.8	15.7	14.5
Other income	0.9	1.0	1.6	1.4	1.5	2.3	1.4	1.8	5	7
ETR (%)	25.0	23.5	24.3	24.0	25.6	25.8	26.2	25.0	24.2	25.6
Adj PAT	12	12	12	11	11	13	11	12	46	46
QoQ (%)	3.4	0.9	0.6	-5.9	3.1	10.3	-13.2	6.1		
YoY (%)	4.1	-2.2	8.2	-1.2	-1.5	7.7	-7.1	4.7	2.1	0.9
EPS (INR)	38.9	39.2	39.4	37.1	38.2	42.2	36.6	38.9	154.5	155.9

### LTTS Neutral

#### CMP INR4,502 | TP: INR4,700 (+4%)

- LTTS guided for 10% YoY CC growth in FY25, with ~8% organic contribution; looks attainable backed by broadbased strength in 4Q. We estimate 15% QoQ CC growth.
- We model EBIT margins at 15% for 4QFY25, down 90bp QoQ due to Intelliswift consolidation (150bp impact) and SG&A investments. Margins shall improve in 1HFY26 on account of tailwinds such as pyramid optimization and operational efficiencies.

#### EPS CHANGE (%): FY25 | 26 | 27: 0.8 | 2.0 | 1.7

- The demand outlook is steadily improving. All verticals shall grow in 4Q. The inorganic contribution from Intelliswift shall help LTTS in achieving its guidance.
- We anticipate FY26 to be better than FY25.We anticipate LTTS to provide growth guidance of 13-15% YoY CC for FY26.

#### **Quarterly Performance**

Y/E March		FY2	4			FY25	iE .		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Revenue (USD m)	280	288	291	305	295	307	312	357	1,164	1,271
QoQ (%)	9.8	2.9	0.9	5.0	-3.2	3.9	1.7	14.6	17.6	9.2
Revenue (INR m)	23,014	23,865	24,218	25,375	24,619	25,729	26,530	30,993	96,472	1,07,871
YoY (%)	22.8	19.6	18.2	21.1	7.0	7.8	9.5	22.1	20.4	11.8
GPM (%)	30.0	28.0	29.2	28.9	29.3	29.3	29.0	28.8	29.0	29.1
SGA (%)	10.4	8.1	9.1	9.1	10.8	11.2	10.3	11.0	9.1	10.8
EBITDA	4,528	4,756	4,877	5,028	4,562	4,660	4,947	5,517	19,189	19,686
EBITDA Margin (%)	19.7	19.9	20.1	19.8	18.5	18.1	18.6	17.8	19.9	18.2
EBIT	3,954	4,075	4,162	4,282	3,836	3,877	4,219	4,649	16,473	16,581
EBIT Margin (%)	17.2	17.1	17.2	16.9	15.6	15.1	15.9	15.0	17.1	15.4
Other income	357	286	493	428	491	531	180	558	1,564	1,760
ETR (%)	27.6	27.6	27.6	27.5	27.5	27.4	27.4	26.5	27.6	27.2
Adj. PAT	3,111	3,154	3,362	3,409	3,136	3,196	3,166	3,827	13,036	13,325
QoQ (%)	0.5	1.4	6.6	1.4	-8.0	1.9	-0.9	20.9		
YoY (%)	13.5	11.7	10.7	10.1	0.8	1.3	-5.8	12.3	11.4	2.2
EPS (INR)	29.4	29.8	31.7	32.2	29.6	29.8	30.4	36.7	123.0	126.4

### Mphasis Neutral

#### CMP INR2,500 | TP: INR2,550 (+2%)

- 4Q is expected to be the best quarter QoQ in the past three years as guided by the company in the previous quarter. We expect 3% QoQ CC growth as the reversal of furloughs will play out in 4Q.
- BFS and Insurance shall grow in 4Q as a gradual recovery is being observed in mortgage business. We anticipate the company can also close good deal wins in 4Q.

- EPS CHANGE (%): FY25 | 26 | 27: -0.5 | -0.7 | -1.1
- We expect a gradual margin increment of 10bp in 4Q, due to workforce optimization and stable amortization. We anticipate continued investment in leadership for large deal cohorts.
- While logistics and TMT may remain dull, commentary around sub-verticals in logistics such as Airlines will be worth tracking.

#### **Quarterly Performance**

Y/E March	FY24 FY25E							FY24	FY25E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	398	398	402	411	410	421	419	430	1,609	1,680
QoQ (%)	-3.4	0.1	1.0	2.1	-0.2	2.7	-0.5	2.7	-6.3	4.4
Revenue (INR m)	32,520	32,765	33,380	34,120	34,225	35,362	35,613	37,343	1,32,785	1,42,543
YoY (%)	-4.7	-6.9	-4.8	1.5	5.2	7.9	6.7	9.4	-3.8	7.3
GPM (%)	29.1	28.9	31.3	31.2	30.8	31.3	31.7	31.8	30.1	31.4
SGA (%)	11.1	10.7	13.3	12.5	12.7	12.9	12.7	12.9	11.9	12.8
EBITDA	5,869	5,956	6,007	6,388	6,185	6,480	6,781	7,058	24,220	26,504
EBITDA Margin (%)	18.0	18.2	18.0	18.7	18.1	18.3	19.0	18.9	18.2	18.6
EBIT	4,995	5,067	4,972	5,080	5,135	5,444	5,458	5,751	20,114	21,788
EBIT Margin (%)	15.4	15.5	14.9	14.9	15.0	15.4	15.3	15.4	15.1	15.3
Other income	263	150	14	143	238	182	235	261	570	916
ETR (%)	24.7	24.9	25.1	24.7	24.7	24.7	24.8	24.8	24.8	24.8
PAT	3,961	3,920	3,736	3,932	4,045	4,234	4,279	4,524	15,549	17,082
QoQ (%)	-2.3	-1.0	-4.7	5.2	2.9	4.7	1.1	5.7		
YoY (%)	-1.5	-6.3	-9.4	-3.0	2.1	8.0	14.5	15.1	-5.1	9.9
EPS (INR)	20.9	20.6	19.6	20.7	21.3	22.2	22.4	23.7	81.8	89.5

### **Persistent Systems**

### Buy

#### CMP INR5,514 | TP: INR6,250 (+13%)

- We expect 4.0% QoQ CC revenue growth. We anticipate growth across key verticals to converge in FY26.
- Margins are expected to remain flat QoQ, supported by steady utilization (83-85%), controlled SG&A investments, absence of wage hikes, and pricing growth.

### EPS CHANGE (%): FY25 | 26 | 27: 0.2 | 0.1 | 0.1

- Commentaries on the demand environment, Healthcare vertical and recovery in Hi-tech vertical are the key things to monitor.
- Deal wins should be healthy in 4Q. We believe a recovery in Hi-Tech and BFSI verticals could strengthen its portfolio in FY26.

#### **Quarterly Performance (IFRS)**

Y/E March		FY2	24			FY2	5E		FY24	FY25E
(Consolidated)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	282.9	291.7	300.6	310.9	328.2	345.5	360.2	374.0	1,186	1,408
QoQ (%)	3.0	3.1	3.0	3.4	5.6	5.3	4.3	3.8	14.5	18.7
Revenue (INR m)	23,212	24,117	24,982	25,905	27,372	28,972	30,623	32,429	98,216	1,19,395
QoQ (%)	3.0	3.9	3.6	3.7	5.7	5.8	5.7	5.9		
YoY (%)	23.6	17.7	15.2	14.9	17.9	20.1	22.6	25.2	17.6	21.6
GPM (%)	34.2	33.1	33.8	33.3	33.0	33.4	34.7	34.0	33.6	33.8
SGA (%)	16.0	16.3	16.1	15.7	16.4	16.8	17.1	16.5	16.0	16.7
EBITDA	4,229	4,052	4,418	4,544	4,552	4,807	5,378	5,675	17,243	20,412
EBITDA Margin (%)	18.2	16.8	17.7	17.5	16.6	16.6	17.6	17.5	17.6	17.1
EBIT	3,466	3,308	3,631	3,744	3,840	4,062	4,557	4,805	14,149	17,264
EBIT Margin (%)	14.9	13.7	14.5	14.5	14.0	14.0	14.9	14.8	14.4	14.5
Other income	90	250	262	210	165	283	263	259	813	971
ETR (%)	22.0	26.0	26.5	20.3	23.5	25.2	22.6	22.9	23.7	23.5
Adj. PAT	2,774	2,633	2,861	3,153	3,064	3,250	3,729	3,906	11,421	13,949
QoQ (%)	10.3	-5.1	8.7	10.2	-2.8	6.1	14.7	4.7		
YoY (%)	31.1	19.7	6.9	25.4	10.5	23.4	30.3	23.9	20.1	22.1
Reported EPS (INR)	15.0	17.3	18.8	20.7	19.9	21.2	24.3	25.5	71.9	90.9

TCS Buy

#### CMP INR3,606 | TP: INR4,050 (+12%)

- TCS is expected to post a revenue decline of 0.5% QoQ CC as BSNL ramp-down starts taking shape. Expect BFSI to remain strong, but manufacturing to be slightly weak
- The deal pipeline should remain healthy. Excl. BSNL, FY26 should be better than FY25 for major countries and core-verticals.

- EPS CHANGE (%): FY25|26| 27: -2.3|-1.3|-1.2
- EBIT margin may remain flat QoQ, aided by operational efficiencies, despite headwinds from talent investments.
   4Q margin should be aided by BSNL tapering, and pyramid benefits from early hiring in 1Q/2Q.
- Outlook on near-term demand & pricing environment, BFSI, and deal wins are key monitorables.

**Quarterly Performance (IFRS)** 

Y/E March		FY2	4			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
IT Services Revenue (USD m)	7,226	7,210	7,281	7,363	7,505	7,670	7,539	7,477	29,080	30,191
QoQ (%)	0.4	-0.2	1.0	1.1	1.9	2.2	-1.7	-0.8	4.1	3.8
Overall Revenue (INR b)	594	597	606	612	626	643	640	648	2,409	2,557
QoQ (%)	0.4	0.5	1.5	1.1	2.2	2.6	-0.4	1.3		
YoY (%)	12.6	7.9	4.0	3.5	5.4	7.7	5.6	5.9	6.8	6.1
GPM (%)	39.5	40.1	40.8	41.1	42.6	38.2	38.8	39.3	40.4	39.7
SGA (%)	16.4	15.8	15.8	15.1	18.0	14.1	14.3	14.8	15.7	15.3
EBITDA	150	157	164	172	167	168	170	172	643	677
EBITDA Margin (%)	25.2	26.3	27.1	28.1	26.7	26.1	26.5	26.6	26.7	26.5
EBIT	138	145	152	159	154	155	157	159	594	624
EBIT Margin (%)	23.2	24.3	25.0	26.0	24.7	24.1	24.5	24.5	24.7	24.4
Other income	12	8	7	9	8	6	10	10	37	33
PBT	150	153	159	168	162	160	167	169	632	658
ETR (%)	25.8	25.8	25.8	25.8	25.4	25.4	25.3	25.5	25.7	25.4
Adj. PAT	111	114	118	125	121	120	124	126	469	491
<b>Exceptional items</b>	0	0	-7	0	0	0	0	0	-7	0
Reported PAT	111	114	111	125	121	120	124	126	462	491
QoQ (%)	-2.8	2.3	-2.5	12.7	-3.2	-1.2	4.1	0.9		
YoY (%)	16.8	8.7	2.0	9.3	8.9	5.1	12.1	0.4	9.3	6.1
EPS (INR)	30.3	31.0	30.3	34.4	33.3	32.9	34.2	34.5	126.3	134.9

#### **Tech Mahindra**

## Buy

#### CMP INR 1,418 | TP: INR1,950 (+37%)

- Revenue growth may decline 0.8% QoQ CC in 4Q due to muted recovery in Telecom and Manufacturing (~50% of revenue). While the communications vertical has stabilized, recovery may take time.
- Margins are expected to rise 10bp despite wage hikes as Project Fortius continues to deliver.

- EPS CHANGE (%): FY25 | 26 | 27: 0.6 | -1.3 | 0.1
- Rate of deal wins saw improvement in 3Q in key verticals such as Telecom and Hi-Tech. We anticipate the company can deliver good deal TCV in 4Q.
- The outlook on segments such as CME, especially in US, and manufacturing verticals, will be the key monitorable.

#### **Quarterly Performance**

Y/E March		FY24	4			FY25	SE .		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	1,601	1,555	1,573	1,548	1,559	1,589	1,567	1,544	6,277	6,259
QoQ (%)	-4.0	-2.8	1.1	-1.6	0.7	1.9	-1.4	-1.5	-5.0	-0.3
Revenue (INR b)	132	129	131	129	130	133	133	134	520	530
YoY (%)	3.5	-2.0	-4.6	-6.2	-1.2	3.5	1.4	4.0	-2.4	1.9
GPM (%)	25.7	22.5	23.9	27.0	26.5	27.9	28.8	27.8	24.8	27.8
SGA (%)	13.5	11.5	13.6	16.1	14.5	14.8	15.2	14.2	13.7	14.7
EBITDA	16	14	14	14	16	18	18	18	58	69
EBITDA Margin (%)	12.2	10.9	10.3	10.9	12.0	13.1	13.6	13.6	11.1	13.1
EBIT	12	9	9	9	11	13	14	14	40	51
EBIT Margin (%)	8.8	7.3	7.0	7.4	8.5	9.6	10.2	10.3	7.6	9.6
Other income	1	2	0	3	1	4	-1	-1	5	4
ETR (%)	21.8	9.9	17.6	23.4	26.7	26.6	23.9	24.5	18.5	25.5
Adj. PAT	10	10	7	10	9	13	10	10	36	41
QoQ (%)	-28.2	2.3	-26.5	34.9	-12.2	46.8	-21.4	1.8		
YoY (%)	-15.5	-25.3	-44.6	-27.1	-10.9	27.8	36.8	3.3	-28.5	12.8
Extra-Ordinary Item	-2.6	-4.8	-2.1	-3.1	0.0	0.0	0.0	0.0	-12.6	0.0
Reported PAT	7	5	5	7	9	13	10	10	24	41
EPS (INR)	10.8	11.0	8.1	11.0	9.6	14.1	11.1	11.3	40.9	46.1

### Wipro

#### CMP INR 262 | TP: INR 240 (-8%)

- WPRO is likely to report flat revenue in 4Q (midpoint of its 4Q guidance) as softness may persist in Energy, Manufacturing and Resources, along with Europe and APMEA regions.
- BFSI may perform better sequentially due to uptick in budgets and Capco business. Healthcare will also grow, but slower than in past.

- **EPS CHANGE (%): FY25 | 26 | 27: 1.0 | 2.3 | 1.1**
- For 4QFY25, margins are expected to remain in a narrow band, with no significant headwinds anticipated. Wage hikes are behind and fully absorbed in 3Q.
- Key monitorable: Commentary on recovery in Europe region also Energy, Manufacturing and resources verticals.

#### **Quarterly Performance (IFRS)**

Y/E March		FY24	ļ.			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
IT Services Revenue (USD m)	2,779	2,713	2,656	2,657	2,626	2,660	2,629	2,608	10,805	10,523
QoQ (%)	-2.1	-2.3	-2.1	0.0	-1.2	1.3	-1.2	-0.8	-3.8	-2.6
Overall Revenue (INR b)	228	225	222	222	220	223	223	227	896	893
QoQ (%)	-1.5	-1.4	-1.4	0.0	-1.1	1.5	0.1	1.7		
YoY (%)	6.0	-0.1	-4.4	-4.2	-3.8	-1.0	0.5	2.2	-0.9	-0.4
GPM (%)	29.4	29.3	30.7	29.2	30.2	30.5	31.0	30.6	29.6	30.6
SGA (%)	14.2	14.6	16.0	13.2	13.7	13.6	13.8	13.0	14.5	13.5
EBITDA	42	42	42	44	44	46	47	48	170	186
EBITDA Margin (%)	18.4	18.8	19.0	19.7	20.2	20.5	21.3	21.3	19.0	20.8
IT Serv. EBIT (%)	16.0	16.1	16.0	16.4	16.5	16.8	16.0	17.6	16.4	17.0
EBIT Margin (%)	15.1	14.8	14.8	15.9	16.4	16.7	17.5	17.5	15.2	17.0
Other income	3	2	3	3	4	6	6	4	11	19
ETR (%)	24.0	24.0	24.0	26.0	24.5	24.6	24.4	24.6	24.5	24.5
PAT	29	26	27	28	30	32	34	33	110	128
QoQ (%)	-6.6	-7.8	1.8	5.2	5.9	6.8	4.5	-2.3		
YoY (%)	12.0	-0.5	-11.7	-7.8	4.6	21.3	24.5	15.6	-2.9	16.5
EPS (INR)	2.6	2.5	2.6	2.7	5.7	3.1	3.2	3.1	10.2	12.2

### **Zensar Technologies**

#### CMP INR 701 | TP: INR 770 (+10%)

- We expect a decline of 0.5% QoQ CC in 4QFY25.
- We anticipate EBITDA margins to improve by 20bp QoQ to 15.7%. The company is likely to exit FY25 in its guided range of mid-teen EBITDA margins.

# Neutral EPS CHANGE (%): FY25|26| 27: -1.5|-1.5|-1.2

- The demand environment in healthcare and life sciences segment remains soft. A significant portion of order book
- Commentary on the deal pipeline, discretionary spending, and client pyramid—given the company's focus on farming efforts—will be key to monitor.

can be concentrated in BFSI and Europe.

#### **Quarterly Performance**

Y/E March		FY24	ļ.			FY25	FY24	FY25E		
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
Revenue (USD m)	149	150	145	148	154	156	157	156	592	624
QoQ (%)	1.2	0.6	-3.7	2.3	4.3	1.2	0.5	-0.5	-2.0	5.3
Revenue (INR m)	12,272	12,408	12,041	12,297	12,881	13,080	13,256	13,550	49,018	52,767
YoY (%)	2.0	0.5	0.5	1.4	5.0	5.4	10.1	10.2	1.1	7.6
GPM (%)	33.6	31.8	31.1	30.6	30.4	28.1	30.1	30.5	31.8	29.8
SGA (%)	14.9	13.2	13.9	14.1	15.2	12.7	14.5	14.8	14.0	14.3
EBITDA	2,301	2,308	2,076	2,030	1,961	2,011	2,069	2,127	8,715	8,169
EBITDA Margin (%)	18.8	18.6	17.2	16.5	15.2	15.4	15.6	15.7	17.8	15.5
EBIT	1,878	1,942	1,764	1,793	1,714	1,714	1,832	1,897	7,377	7,157
EBIT Margin (%)	15.3	15.7	14.6	14.6	13.3	13.1	13.8	14.0	15.0	13.6
Other income	224	306	356	493	383	366	270	304	1,379	1,323
ETR (%)	25.7	22.7	23.8	24.2	24.7	25.1	24.0	24.5	24.1	24.6
Adj. PAT	1,562	1,738	1,616	1,733	1,579	1,558	1,597	1,661	6,649	6,395
QoQ (%)	30.9	11.3	-7.0	7.2	-8.9	-1.3	2.5	4.0		
YoY (%)	108.0	206.0	111.2	45.3	1.1	-10.4	-1.2	-4.2	102.9	-3.8
EPS (INR)	6.8	7.6	7.1	7.6	6.9	6.8	7.0	7.3	29.1	28.0

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

### NOTES

Explanation of Investment Rating								
Investment Rating	Expected return (over 12-month)							
BUY	>=15%							
SELL	< - 10%							
NEUTRAL	< - 10 % to 15%							
UNDER REVIEW	Rating may undergo a change							
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation							

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### **Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations)

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at xy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

#### **Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes. Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
- MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report. MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- 5 Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months. 6.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

  MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.

March 2025 13

- 9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- 10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of

Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085. Grievance Redressal Cell:

Chevanos realizada con.									
Contact Person	Contact No.	Email ID							
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com							
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com							
Mr. Ajay Menon	022 40548083	am@motilaloswal.com							

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.